Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis

Gilhus, 2015, Myasthenia gravis: subgroup classification and therapeutic strategies, Lancet Neurol., 14, 1023, 10.1016/S1474-4422(15)00145-3 Gold, 2008, Progress in the treatment of myasthenia gravis, Ther. Adv. Neurol. Disord., 1, 36, 10.1177/1756285608093888 Jenkins, 1972, Treatment of myasthenia gravis with prednisone, Lancet, 1, 765, 10.1016/S0140-6736(72)90520-X Brunner, 1972, Corticosteroids in management of severe, generalized myasthenia gravis. Effectiveness and comparison with corticotropin therapy, Neurology, 22, 603, 10.1212/WNL.22.6.603 Seybold, 1974, Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment, N. Engl. J. Med., 290, 81, 10.1056/NEJM197401102900204 Mann, 1976, Long-term administration of corticosteroids in myasthenia gravis, Neurology, 26, 729, 10.1212/WNL.26.8.729 Bae, 2006, Clinical predictors of steroid-induced exacerbation in myasthenia gravis, J. Clin. Neurosci., 13, 1006, 10.1016/j.jocn.2005.12.041 Chung, 1984, A clinical study on crisis in myasthenia gravis, J. Korean Neurol. Assoc., 2, 29 Jaretzki, 2000, Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America, Neurology, 55, 16, 10.1212/WNL.55.1.16 Akaike, 1974, A new look at the statistical model identification, IEEE Trans. Autom. Control, 19, 716, 10.1109/TAC.1974.1100705 Muppidi, 2017, Outcome measures in Myasthenia Gravis: incorporation into clinical practice, J. Clin. Neuromuscul. Dis., 18, 135, 10.1097/CND.0000000000000156 Evoli, 1992, Long-term results of corticosteroid therapy in patients with myasthenia gravis, Eur. Neurol., 32, 37, 10.1159/000116785 Pascuzzi, 1984, Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients, Ann. Neurol., 15, 291, 10.1002/ana.410150316 Wilson, 1974, Corticosteroids: a direct effect at the neuromuscular junction, Neurology, 24, 1091, 10.1212/WNL.24.11.1091 Miller, 1986, Prednisone-induced worsening of neuromuscular function in myasthenia gravis, Neurology, 36, 729, 10.1212/WNL.36.5.729 Arsura, 1985, High-dose intravenous methylprednisolone in myasthenia gravis, Arch. Neurol., 42, 1149, 10.1001/archneur.1985.04060110031011 Kim, 2004, Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report, Lung Cancer, 44, 369, 10.1016/j.lungcan.2003.12.010 Howard, 2011, The tumor lysis syndrome, N. Engl. J. Med., 364, 1844, 10.1056/NEJMra0904569 Namba, 1978, Myasthenia gravis in patients with thymoma, with particular reference to onset after thymectomy, Medicine (Baltimore), 57, 411, 10.1097/00005792-197809000-00002 Vacchio, 1998, A positive role for thymus-derived steroids in formation of the T-cell repertoire, Ann. N. Y. Acad. Sci., 840, 317, 10.1111/j.1749-6632.1998.tb09571.x